HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals Plc has announced that its Annual Report and Accounts for the year ending December 31, 2023, along with the Notice of its upcoming Annual General Meeting (AGM) and related proxy materials, have been distributed to shareholders and are available on the company’s website. The AGM is scheduled for June 27, 2024, at the offices of SP Angel Corporate Finance LLP in London. HemoGenyx Pharmaceuticals is a pre-clinical stage biopharmaceutical company focused on developing new treatments for blood and autoimmune diseases and improving bone marrow transplantation for life-threatening conditions.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
